Last reviewed · How we verify
autologous CAR.CD30 EBV specific-CTLs — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
autologous CAR.CD30 EBV specific-CTLs (autologous CAR.CD30 EBV specific-CTLs) — Baylor College of Medicine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| autologous CAR.CD30 EBV specific-CTLs TARGET | autologous CAR.CD30 EBV specific-CTLs | Baylor College of Medicine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- autologous CAR.CD30 EBV specific-CTLs CI watch — RSS
- autologous CAR.CD30 EBV specific-CTLs CI watch — Atom
- autologous CAR.CD30 EBV specific-CTLs CI watch — JSON
- autologous CAR.CD30 EBV specific-CTLs alone — RSS
Cite this brief
Drug Landscape (2026). autologous CAR.CD30 EBV specific-CTLs — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-car-cd30-ebv-specific-ctls. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab